Plus   Neg

INOVIO Presents Data From Combination Trial Of INO-5401 And INO-9012 With Libtayo

INOVIO (INO) said data from the combination trial of INO-5401 and INO-9012 showed that the DNA medicines in combination with PD-1 inhibitor Libtayo (cemiplimab), radiation and temozolomide are tolerable, immunogenic, and may improve median survival for patients with newly diagnosed glioblastoma. The company said the combination of INO-5401 + INO-9012 continues to show a well-tolerated safety profile when given not only with radiation and temozolomide, but also with PD-1 blockade by Libtayo, which is being jointly developed by Regeneron and Sanofi.

Jeffrey Skolnik, INOVIO's senior vice president, clinical development, said, "INO-5401 + INO-9012, with Libtayo and RT/TMZ, generates cancer antigen-specific T cells that may be able to attack GBM and provide a survival advantage."

The company will provide additional data in the coming months, including correlative immunology and tissue data, as well as total study drug exposure and concomitant medication use.

For comments and feedback contact: editorial@rttnews.com

Business News

Follow RTT